



FOR IMMEDIATE RELEASE

ETUBICS PRESENTS "NEXT GENERATION" OF ADENOVIRUS VACCINE AT LIFE SCIENCE INNOVATION NORTHWEST

SEATTLE (March 11, 2010) – Etubics Corporation will report on a novel "next generation" therapeutic adenovirus vaccine platform at Life Science Innovation Northwest at the Bell Harbor International Conference Center in the Sound Conference Room at 2:35 p.m. on Tuesday, March 16, 2010. This will be followed by a question and answer period in the Coastal Room. Etubics' "next generation" vector vaccines overcome many of the challenges presented by first generation adenovirus vaccines and are currently in clinical trials for the treatment of colon cancer.

"As it became apparent during the recent H1N1 pandemic, our current vaccine methods are incapable of efficiently and quickly dealing with a world-wide health disasters and a new method must be created," said Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics. "Clinical studies at leading universities around the country will enhance our promise that Etubics' human cell based novel vector vaccine platform can overcome this issue for not just pandemic vaccines, but also therapeutic vaccines for hard to treat cancers and HIV."

Etubics' utilized its "next generation" vector vaccine platform with their patented E.C7 human cell line technology as a gene delivery vehicle that can be used to efficiently develop preventative and treatment vaccines against a wide range of infectious diseases and cancers. Through grants from the National Institute of Health, Etubics is pursuing: therapeutic vaccines for colon cancer and breast cancer; and prevention vaccines for swine flu (H1N1), malaria and HIV.

Pre-clinical trials of Etubics "next generation" vector vaccines have proven the technology to be superior to other adenovirus vaccines because they:

- **Can be delivered multiple times.** The additional genetic deletions of our adenovirus serotype 5 vectors allows the delivery platform to be dispensed multiple times to the same vaccinee. This overcomes the barrier of immunity to current adenovirus vector platforms, resulting in increased immunity.
- **Have a reduced production of vaccine capsid proteins, making them more efficient.** Early generation adenovirus vectors had a high level of capsid proteins, resulting in unwanted immunologic reactions. Etubics' vaccines do not induce this immunologic confusion, which has been proven to be partly responsible for the older generations adenoviral vector's malfunction.
- **Offers a greater vaccination capacity, making a more effective product.** Conventional vector platforms have a relatively low functional capacity, causing scientist to decide which proteins to include. Often each person has a different immune response to each protein, which means that no single choice of a disease target would protect everyone. Etubics vectors can included the entire genome of a disease, such as HIV, obviating the need to choose proteins and allowing the body to make the decision about which protein it will mount immunity against, not the scientist.

Etubics "next generation" vector vaccine platform has been researched in the scientific laboratory for more than 12 years. Over \$18 million has been invested in the technology primarily through grants from the National Institute of Health and investment capital. Etubics has acquired an exclusive worldwide license

agreement from the University of Michigan for the rights to develop certain patents pertaining to the vector vaccine platform.

About Life Science Innovation Northwest

The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company are proud to present the region's 10th annual "Life Science Innovation Northwest" conference in Seattle. Innovation has supercharged the Pacific Northwest's biotech and medical device industries for decades. Our life sciences companies, non-profit research institutes and global health organizations are leading the way. And, we are pushing forward some of the most compelling technology breakthroughs of our time. As such, this year's forum--formerly "Invest Northwest"--has been refocused and rebranded to better identify and highlight these unique and powerful assets, defining the Pacific Northwest's life sciences sector. Learn more and register at <http://www.washbio.org/>.

About Etubics

Etubics Corporation is a Seattle based biopharmaceutical company developing "next generation" vector vaccines to immunize and treat large worldwide populations from difficult to treat diseases such as select cancers, influenza viruses, HIV, and malaria. Etubics patent-protected pharmaceuticals, called adenovirus vectors, are safer, more effective, more versatile and easier to produce than competing products. They can also be utilized to re-immunize a vaccinee, solving a current challenge in the industry. Etubics was established in 2005, by Dr. Frank Jones, using technology from the University of Michigan, and is currently engaged in research, development and commercialization of its proprietary and novel adenovirus vector vaccine products. For more information on Etubics, visit www.etubics.com.

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of Etubics proposed candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics business, financial conditions and results of operations, are contained in Etubics's documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

###

Investor/Media contact: Kimberly Jones
Phone: (206) 838-5110 Ext. 110
kimberly@etubics.com